Bank of America’s RAPT Therapeutics RAPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-58,330
Closed -$1.98M 6636
2025
Q4
$1.98M Buy
58,330
+54,359
+1,369% +$1.69M ﹤0.01% 4081
2025
Q3
$102K Sell
3,971
-2,942
-43% -$38.5K ﹤0.01% 6581
2025
Q2
$55.3K Sell
6,913
-22,996
-77% -$175K ﹤0.01% 6778
2025
Q1
$292K Sell
29,909
-7,601
-20% -$74.7K ﹤0.01% 5963
2024
Q4
$474K Buy
37,510
+69
+0.2% +$876 ﹤0.01% 5574
2024
Q3
$602K Buy
37,441
+26,109
+230% +$528K ﹤0.01% 5376
2024
Q2
$277K Sell
11,332
-2,325
-17% -$107K ﹤0.01% 5717
2024
Q1
$981K Buy
13,657
+1,981
+17% +$275K ﹤0.01% 4945
2023
Q4
$2.32M Buy
11,676
+87
+0.8% +$10.8K ﹤0.01% 4255
2023
Q3
$1.54M Buy
11,589
+2,401
+26% +$392K ﹤0.01% 4494
2023
Q2
$1.37M Sell
9,188
-8,217
-47% -$1.28M ﹤0.01% 4535
2023
Q1
$2.55M Sell
17,405
-493
-3% -$99.7K ﹤0.01% 4131
2022
Q4
$2.84M Buy
17,898
+11,731
+190% +$1.88M ﹤0.01% 3942
2022
Q3
$1.19M Buy
6,167
+5,044
+449% +$954K ﹤0.01% 4749
2022
Q2
$164K Sell
1,123
-3,392
-75% -$452K ﹤0.01% 6226
2022
Q1
$794K Sell
4,515
-5,764
-56% -$1.09M ﹤0.01% 5453
2021
Q4
$3.02M Buy
10,279
+9,138
+801% +$2.44M ﹤0.01% 4158
2021
Q3
$283K Buy
1,141
+154
+16% +$40.7K ﹤0.01% 6049
2021
Q2
$250K Buy
987
+17
+2% +$3.18K ﹤0.01% 5944
2021
Q1
$172K Buy
970
+411
+74% +$67.8K ﹤0.01% 6131
2020
Q4
$88K Buy
559
+94
+20% +$20.4K ﹤0.01% 6050
2020
Q3
$120K Sell
465
-2,394
-84% -$531K ﹤0.01% 5588
2020
Q2
$663K Buy
2,859
+2,787
+3,871% +$431K ﹤0.01% 4414
2020
Q1
$12K Buy
72
+42
+140% +$9.57K ﹤0.01% 6311
2019
Q4
$7K Buy
+30
New +$5.52K ﹤0.01% 6708

Bank of America's RAPT Position: Q1 2026 in Review

Bank of America sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 58,330 shares — an estimated $1.98M sold.

Bank of America first reported a position in RAPT in Q4 2019 and held it in 25 quarters. The position peaked at $3.02M in Q4 2021. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

  • Bank of America reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 58,330 RAPT Therapeutics shares in Q1 2026, an estimated $1.98M.
  • Bank of America first reported a position in RAPT Therapeutics in Q4 2019 and held it in 25 quarters.
  • Bank of America's RAPT Therapeutics position peaked at $3.02M in Q4 2021.
  • 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.